Albert Bourla, CEO of Pfizer, announced that the company — along with other pharmaceutical firms — has been in talks with the Trump administration to lower drug prices in the U.S. However, no clear agreement has been reached so far.
Last month, President Trump issued an executive order calling for drug prices in the U.S. to be aligned with those paid in other developed countries. Under the order, the government was tasked with establishing a “Most Favored Nation” pricing mechanism within 30 days.
However, it remains unclear what exact strategy the U.S. government will use to enforce lower drug prices. Analysts and legal experts have warned that implementing this policy could face significant challenges.
